- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05296941
Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD) (PMOD)
September 6, 2023 updated by: Kristina Edman, Dalarna County Council, Sweden
Screening for Oral Cancer for Early Detection of Premalignant Disorders
Cancer is a complex disease; its different causes and types have a strong impact on patient treatment and prognosis.
To improve understanding of the disease, its causes and progression, the investigators will develop a simple, cost-effective system for continuous control of mucosal lesions with non-invasive brush biopsy that can be managed in primary dental care, as an alternative to tissue biopsy in order to reduce the number of oral cavity cancers.
Study Overview
Detailed Description
In Sweden, about 1,200 cases of cancer of the oral cavity, lips and throat are diagnosed each year.
This is significantly higher than the global age-standardized incidence of 6.1 per 100,000 inhabitants, including all ages and genders.
Oral cancer is a serious and growing public health problem and leads to significantly reduced quality of life after extensive treatment that usually includes radiation therapy and surgery.
Patients often have pain, swallowing problems, dry mouth that causes tooth status, negatively affected appearance, family life and social interaction.
Although it is well known that early diagnostic screening is of great importance for increasing survival, there is a lack of a nationally organized screening program of high-risk individuals, tobacco users and individuals with overconsumption of alcohol.
As a result, many cases are diagnosed late and therefore have poor prognosis.
The five-year survival rate in Sweden for the diagnosis of oral cancer is about 60%.
If the tumor is small when diagnosed, without lymph node involvement or metastases,and treated correctly, a survival rate of 90% can be achieved while in a late diagnosis with the presence of lymph node involvement and metastases, survival drops drastically and is only 36%.
A large proportion of oral cancer originates from potentially malignant oral mucosal lesions (PMOD) that occur in a prevalence of about 2-3% globally and over time are at risk of malignification.
Of PMOD, oral leukoplakia (OL) is the most prevalent and most common in the group of middle-aged or older men.
Swedish prevalence figures for OL have been reported to range from 0.7% to 3.5%.
As patients with PMOD such as OL, erythroplakia (EP) or proliferative verrukös are at a significantly increased risk of developing oral cancer, it is important to include these patients in a functioning control system.
This is especially true for risk individuals, those with an overconsumption of alcohol, with tobacco use, and those with chronic infection of tonsil and tongue base with high-risk human papillomavirus.
About 80% of the adult population in Sweden is regularly examined at private dental care or public dental care, which means that general dental care can take a great responsibility for identifying and carrying out continuous checks on risk groups.
A routine examination of the patient should include assessment of the oral mucosa according to clinical practice.
Oral mucosal changes should be diagnosed and, if necessary, treatment initiated.
In the case of a clinical diagnosis of OL, EP or verrukös leukoplakia, the clinical diagnosis should be verified with a tissue biopsy performed at a specialist clinic in orofacial medicine, oral surgery or ear-nose-throat clinic.
Based on the diagnosis and degree of cell changes, it is decided according to current practice whether the continued treatment and the patient is included in a system for continuous checks.
Oral cancer must be diagnosed early because mortality is high, especially in late diagnosis, and quality of life after treatment is very poor with significant pain, speech, chewing and swallowing difficulties with a strong impact on both family life and social contacts and working life.
The solution is early detection and early treatment, which can be achieved if follow-up are performed in primary dental care with non-invasive brush biopsies for cytological diagnostics in a similar way to cervical cancer screening managed by midwives.
Cytological diagnosis of oral mucosal changes is a safe, simple and rapid method with high sensitivity and specificity.
With the present series of studies, the investigators intend to evaluate different possibilities to identify PMOD with high-grade dysplasias, and tumors early in order to improve prognosis.
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kristina Edman, PhD
- Phone Number: +46(0)70 5349476
- Email: kristina.edman@regiondalarna.se
Study Contact Backup
- Name: Jan-Michael Hirsch
- Email: jan.hirsch@sll.se
Study Locations
-
-
Dalarna
-
Falun, Dalarna, Sweden, 79129
- Recruiting
- Kristina Edman
-
Contact:
- Kristina Edman, PhD
- Phone Number: +46705349476
- Email: kristina.edman@regiondalarna.se
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
• Persons 18 years of age or older who have the clinical diagnosis of leukoplakia, erythroplakia or proliferative verrukös leukoplakia
Exclusion Criteria:
- People who cannot read and understand information in Swedish.
- Ongoing chemotherapy and/or radiotherapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brush biopsy
Brusch biopsy at baseline and at 3 or 6 months
|
Brush sampling instead of surgical biopsy for control of reaccurance
|
Active Comparator: Care as usual
Control at 3 or 6 month, surgical biopsy when needed
|
Brush sampling instead of surgical biopsy for control of reaccurance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Numbers of cancers diagnosed by brush sampling
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Public dental care, Uppsala University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2023
Primary Completion (Estimated)
December 31, 2029
Study Completion (Estimated)
December 31, 2029
Study Registration Dates
First Submitted
March 8, 2022
First Submitted That Met QC Criteria
March 22, 2022
First Posted (Actual)
March 25, 2022
Study Record Updates
Last Update Posted (Actual)
September 8, 2023
Last Update Submitted That Met QC Criteria
September 6, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Public dental care
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mouth Neoplasms
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Department of Health and Human ServicesTerminated
-
Region Örebro CountyCompletedTongue Cancer | Floor of Mouth Squamous Cell CarcinomaSweden
-
Tata Memorial HospitalTata Memorial CentreNot yet recruiting
-
University Hospital, ToulouseCompleted
-
VA Office of Research and DevelopmentCompletedMouth NeoplasmsUnited States
-
Shanghai Ninth People's Hospital Affiliated to...UnknownPrecancerous Conditions | Oral Cavity Cancer | Mouth NeoplasmChina
-
hassan harby mohamedNot yet recruiting
-
NYU Langone HealthCompleted
Clinical Trials on Brush sampling
-
Milton S. Hershey Medical CenterRecruitingCervical Cancer ScreeningUnited States
-
Milton S. Hershey Medical CenterCompleted
-
The Institute of Molecular and Translational Medicine...Cancer Research Czech RepublicRecruitingCervical Cancer | Human Papillomavirus Infection | Cervical DysplasiaCzechia
-
University of Colorado, DenverNational Jewish HealthRecruitingObesity | Metabolic Syndrome | AsthmaUnited States
-
Milton S. Hershey Medical CenterTerminated
-
University Hospital, LilleMinistry of Health, FranceCompletedCervical Intraepithelial Neoplasia | Malignant Tumor of CervixFrance
-
University of AarhusAarhus University Hospital; Bandim Health Project; Universiteit Antwerpen; Randers...RecruitingHIV Infections | Cervical Cancer | HPV-Related Cervical Carcinoma | Coinfection, HIVGuinea-Bissau
-
The Institute of Molecular and Translational Medicine...Cancer Research Czech RepublicCompletedCervical Cancer | Human Papillomavirus Infection | Cervical DysplasiaCzechia
-
Washington University School of MedicineActive, not recruitingPregnancy Related | Innate Inflammatory ResponseUnited States
-
Institut d'Investigació Biomèdica de BellvitgeInstitut Català d'Oncologia; Institut Català de la Salut; Complejo Hospitalario...RecruitingCervical Cancer Screening | HPV-Related Cervical Carcinoma | Self-samplingSpain